- Home
- RVPHW vs GPRO Comparison
RVPHW vs GPRO Comparison
Compare RVPHW & GPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- GPRO
- Stock Information
- Founded
- RVPHW N/A
- GPRO 2004
- Country
- RVPHW United States
- GPRO United States
- Employees
- RVPHW 15
- GPRO N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- GPRO Industrial Machinery/Components
- Sector
- RVPHW Health Care
- GPRO Consumer Discretionary
- Exchange
- RVPHW Nasdaq
- GPRO Nasdaq
- Market Cap
- RVPHW N/A
- GPRO N/A
- IPO Year
- RVPHW 2018
- GPRO 2014
- Fundamental
- Price
- RVPHW $0.09
- GPRO $1.30
- Analyst Decision
- RVPHW
- GPRO Sell
- Analyst Count
- RVPHW 0
- GPRO 2
- Target Price
- RVPHW N/A
- GPRO $2.25
- AVG Volume (30 Days)
- RVPHW N/A
- GPRO 1.0M
- Earning Date
- RVPHW N/A
- GPRO 11-05-2024
- Dividend Yield
- RVPHW N/A
- GPRO N/A
- EPS Growth
- RVPHW N/A
- GPRO N/A
- EPS
- RVPHW N/A
- GPRO N/A
- Revenue
- RVPHW N/A
- GPRO $931,412,000.00
- Revenue This Year
- RVPHW N/A
- GPRO N/A
- Revenue Next Year
- RVPHW N/A
- GPRO $6.42
- P/E Ratio
- RVPHW N/A
- GPRO N/A
- Revenue Growth
- RVPHW N/A
- GPRO N/A
- 52 Week Low
- RVPHW N/A
- GPRO $1.16
- 52 Week High
- RVPHW N/A
- GPRO $3.80
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- GPRO 47.99
- Support Level
- RVPHW N/A
- GPRO $1.27
- Resistance Level
- RVPHW N/A
- GPRO $1.38
- Average True Range (ATR)
- RVPHW 0.00
- GPRO 0.05
- MACD
- RVPHW 0.00
- GPRO -0.00
- Stochastic Oscillator
- RVPHW 0.00
- GPRO 20.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.